MetaCap

Anbio Biotechnology Class A (NNNN)

NASDAQ: NNNNHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

3.32-0.33 (-9.04%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NNNN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$145.72M
52-week range
3.09 – 44.73
Day range
3.31 – 3.93
Volume / Avg
79.51K / 128.35K
Beta
—

52-week range

$3.09$44.73

NNNN stock today

On Nov 20, NNNN ended the session at $3.32, shedding $0.33 (9.04%), versus the S&P 500's 3.70% decline. At this level, NNNN sits near the bottom of its 52-week range of $3.09 to $44.73: 92.6% below the high, set on Dec 5, 2025 and 7.4% above the low. NNNN is down 89.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 86.0%.

Anbio Biotechnology trades at 22.1x its trailing twelve-month earnings per share of $0.15.

Summary generated from market data by MetaCap's automated system. Methodology

About Anbio Biotechnology

Company profile

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Michael Lau M.B.A., Ph.D.
Headquarters
Frankfurt am Main
Employees
27
IPO year
2025

Financial highlights

Full financials

In fiscal 2025, Anbio Biotechnology generated $8.6 million in revenue, up 5.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $6.4 million (+169.9% year over year), for a net margin of 74.1% versus a median of 33.6% in the prior 3 years. Gross margin was 87.2% (up from 71.9%) and operating margin 66.7%.

Anbio Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$8.65M$8.19M$6.71M$23.54M
Growth+5.64%+21.95%-71.49%—
Net income$6.40M$2.37M$2.25M$10.01M
EPS (diluted)$0.147$0.056$0.105$100,112.00

Anbio Biotechnology peers

Health Care sector
NNNN peer companies
CompanyPrice% ChgMarket capCompare
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs NNNN
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs NNNN
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs NNNN
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs NNNN
BMRABiomerica Inc.1.08-0.92%$4.97Mvs NNNN
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs NNNN
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs NNNN
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs NNNN

Indexes, lists and sector

Anbio Biotechnology stock FAQ

What is Anbio Biotechnology's stock price today?

NNNN last traded at $3.32 as of Nov 20, 4:00 PM EST, down 9.04% on the day. Prices are delayed at least 15 minutes.

What is NNNN's P/E ratio?

NNNN trades at a trailing P/E ratio of 22.13.

Who is Anbio Biotechnology's CEO?

Mr. Michael Lau M.B.A., Ph.D. is the chief executive officer of Anbio Biotechnology Class A, which has about 27 employees.

What is the NNNN 52-week high?

The 52-week high for NNNN is $44.73 and the 52-week low is $3.09. The stock is currently 92.6% below its high.

Compare NNNN